Dermatología

Psoriasis

Biologic therapy (IL-17, IL-23 inhibitors) and JAK inhibitors at fraction of Western cost.

Opciones de Tratamiento

Centros Recomendados

$2,500

Desde

7-21 días

Espera Típica

Planes de Tratamiento para Psoriasis

Compare opciones basadas en evidencia en los principales hospitales chinos — precios transparentes, tiempos de espera y recuperación.

Plan Principal

IL-17 Inhibitor Induction (3 months)

Secukinumab/ixekizumab loading regimen for severe psoriasis.

Tiempo de Espera

5-7 days

Estancia Hospitalaria

12 weeks

Recuperación

Outpatient

Precio Estimado

Approx. $3,200

Ver Introducción Detallada — Procedimiento, Comparación de Precios y Más

Comparación de Precios: China vs EE.UU.

🇨🇳 China

$2,500

🇺🇸 EE.UU.

$12,500+

Ahorre hasta $10,000 por tratamiento

Pasos del Procedimiento

Pre-treatment: BSA assessment + PASI score + tuberculosis screening + hepatitis B/C

Initiation: secukinumab 300mg SC Weeks 0, 1, 2, 3, 4, then monthly

OR ixekizumab: 160mg loading, then 80mg Q2W × 12 weeks, then Q4W

Patient education: injection training + side effect recognition

Weekly self-injection at home after first 4 weeks

Every 3 months: PASI assessment + safety labs

Monitor for candidiasis, IBD flare (risk with IL-17 blockade)

Long-term maintenance → disease remission possible

What are IL-17 Inhibitors?

Biologics targeting IL-17A (secukinumab, ixekizumab) produce rapid, profound skin clearance in moderate-severe plaque psoriasis. They achieve PASI 90 (90% clearance) in the majority of patients — a remarkable improvement over older systemic therapies.

Why China?

Cost (annual): $8,000-$14,000 (domestic patient assistance) vs. $65,000-$85,000 in the US
Multiple options: Secukinumab, ixekizumab, netakimab all NMPA-approved
Dedicated biologic centers: Huashan, Peking Union, Changhai — rheum+derm integration
Biosimilars emerging: Additional cost reduction over next 1-2 years

Who is a candidate?

Moderate-severe plaque psoriasis (BSA >10% or PASI >10)
Psoriatic arthritis
Ankylosing spondylitis
Failed or intolerant to conventional systemics + MTX
Exclude: active TB, active IBD

Outcomes

PASI 75 at 12 weeks: 85-90%. PASI 90: 70-75%. PASI 100 (complete clearance): 40-50%. Rapid onset: significant improvement by Week 2-4. Long-term durability: 5+ years with continued therapy.

Reservar Consulta Gratuita WhatsApp

Los precios son rangos indicativos en USD basados en tarifas publicadas. La cotización final depende de sus registros médicos y hospital seleccionado — solicite una estimación personalizada gratuita.